Clinical Implications of Peak Inspiratory Flow in COPD: Post Hoc Analyses of the TRONARTO Study

References

• Lopez-Campos JL, Calero C, Quintana-Gallego E. Symptom variability in COPD: a narrative review. Int J Chron Obstruct Pulmon Dis. 2013;8:231–238. doi:10.2147/COPD.S42866
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: 2023 report; 2022. Available from: https://goldcopd.org/wp-content/uploads/2022/11/GOLD-2023-ver-1.0-14Nov2022_WMV.pdf. Accessed November 17, 2022.
   Google Scholar
• Usmani OS. Choosing the right inhaler for your asthma or COPD patient. Ther Clin Risk Manag. 2019;15:461–472. doi:10.2147/TCRM.S160365
   PubMed Web of Science ®Google Scholar
• Mahler DA. The role of inspiratory flow in selection and use of inhaled therapy for patients with chronic obstructive pulmonary disease. Respir Med. 2020;161:105857.
   PubMed Web of Science ®Google Scholar
• Represas-Represas C, Aballe-Santos L, Fernandez-Garcia A, et al. Evaluation of suboptimal peak inspiratory flow in patients with stable COPD. J Clin Med. 2020;9(12):3949. doi:10.3390/jcm9123949
   PubMed Web of Science ®Google Scholar
• Kocks J, Wouters H, Bosnic-Anticevich S, et al. Factors associated with health status and exacerbations in COPD maintenance therapy with dry powder inhalers. NPJ Prim Care Respir Med. 2022;32(1):18. doi:10.1038/s41533-022-00282-y
   PubMed Web of Science ®Google Scholar
• Ghosh S, Pleasants RA, Ohar JA, Donohue JF, Drummond MB. Prevalence and factors associated with suboptimal peak inspiratory flow rates in COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:585–595. doi:10.2147/COPD.S195438
   PubMed Web of Science ®Google Scholar
• Loh CH, Peters SP, Lovings TM, Ohar JA. Suboptimal inspiratory flow rates are associated with chronic obstructive pulmonary disease and all-cause readmissions. Ann Am Thorac Soc. 2017;14(8):1305–1311. doi:10.1513/AnnalsATS.201611-903OC
   PubMed Web of Science ®Google Scholar
• Ghosh S, Ohar JA, Drummond MB. Peak inspiratory flow rate in chronic obstructive pulmonary disease: implications for dry powder inhalers. J Aerosol Med Pulm Drug Deliv. 2017;30(6):381–387. doi:10.1089/jamp.2017.1416
   PubMed Web of Science ®Google Scholar
• Virchow JC, Crompton GK, Dal Negro R, et al. Importance of inhaler devices in the management of airway disease. Respir Med. 2008;102(1):10–19.
   PubMed Web of Science ®Google Scholar
• Capstick TG, Clifton IJ. Inhaler technique and training in people with chronic obstructive pulmonary disease and asthma. Expert Rev Respir Med. 2012;6(1):91–101; quiz 102–103. doi:10.1586/ers.11.89
   Web of Science ®Google Scholar
• Newman SP. Inhaler treatment options in COPD. Eur Resp Rev. 2005;14(96):102–108. doi:10.1183/09059180.05.00009605
   Google Scholar
• Mahler DA. Peak inspiratory flow rate as a criterion for dry powder inhaler use in chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2017;14(7):1103–1107. doi:10.1513/AnnalsATS.201702-156PS
   PubMed Web of Science ®Google Scholar
• Sulaiman I, Cushen B, Greene G, et al. Objective assessment of adherence to inhalers by patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;195(10):1333–1343.
   PubMed Web of Science ®Google Scholar
• Dhand R, Eicher J, Hansel M, Jost I, Meisenheimer M, Wachtel H. Improving usability and maintaining performance: human-factor and aerosol-performance studies evaluating the new reusable Respimat inhaler. Int J Chron Obstruct Pulmon Dis. 2019;14:509–523. doi:10.2147/COPD.S190639
   PubMed Web of Science ®Google Scholar
• Hochrainer D, Holz H, Kreher C, Scaffidi L, Spallek M, Wachtel H. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers. J Aerosol Med. 2005;18(3):273–282. doi:10.1089/jam.2005.18.273
   PubMedGoogle Scholar
• Mahler DA, Ludwig-Sengpiel A, Ferguson GT, et al. TRONARTO: a randomized, placebo-controlled study of tiotropium/olodaterol delivered via soft mist inhaler in COPD patients stratified by peak inspiratory flow. Int J Chron Obstruct Pulmon Dis. 2021;16:2455–2465. doi:10.2147/COPD.S324467
   PubMed Web of Science ®Google Scholar
• Mahler D, Watz H, Ritz J, Gardev A, Shaikh A, Drummond M. The variability of peak inspiratory flow: analyses of the TRONARTO population. Poster presented at American Thoracic Society (ATS) International Conference; 13–18 May, 2022; San Francisco, CA, USA.
   Google Scholar
• Mahler DA, Watz H, Emerson-Stadler R, Ritz J, Shaikh A, Drummond MB. The variability of peak inspiratory flow: analyses of the TRONARTO population. Poster presented at European Respiratory Society International Congress (ERS); 4–6 September, 2022; Barcelona, Spain.
   Google Scholar
• Leving MT, Kocks J, Bosnic-Anticevich S, Dekhuijzen R, Usmani OS. Relationship between peak inspiratory flow and patient and disease characteristics in individuals with COPD-a systematic scoping review. Biomedicines. 2022;10(2):458. doi:10.3390/biomedicines10020458
   PubMed Web of Science ®Google Scholar
• Drummond M, Watz H, Ritz J, Gardev A, Shaikh A, Mahler D. Relationship between peak inspiratory flow and patient characteristics: analysis of trends from the TRONARTO population. Poster presented at American Thoracic Society (ATS) International Conference; 13–18 May; 2022; San Francisco, CA, USA.
   Google Scholar
• Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J. 2016;47(2):410–419. doi:10.1183/13993003.01359-2015
   PubMed Web of Science ®Google Scholar
• Cardoso J, Ferreira AJ, Guimaraes M, Oliveira AS, Simao P, Sucena M. Treatable traits in COPD - a proposed approach. Int J Chron Obstruct Pulmon Dis. 2021;16:3167–3182.
   PubMed Web of Science ®Google Scholar
• McDonald VM, Fingleton J, Agusti A, et al. Treatable traits: a new paradigm for 21st century management of chronic airway diseases: Treatable Traits Down Under International Workshop report. Eur Respir J. 2019;53(5):1802058. doi:10.1183/13993003.02058-2018
   PubMed Web of Science ®Google Scholar
• McDonald VM, Osadnik CR, Gibson PG. Treatable traits in acute exacerbations of chronic airway diseases. Chron Respir Dis. 2019;16:1479973119867954. doi:10.1177/1479973119867954
   Web of Science ®Google Scholar
• Agusti A, Bafadhel M, Beasley R, et al. Precision medicine in airway diseases: moving to clinical practice. Eur Respir J. 2017;50(4):1701655. doi:10.1183/13993003.01655-2017
   PubMed Web of Science ®Google Scholar
• Blakey JD, Bender BG, Dima AL, Weinman J, Safioti G, Costello RW. Digital technologies and adherence in respiratory diseases: the road ahead. Eur Resp J. 2018;52(5):1801147.
   PubMed Web of Science ®Google Scholar
• Mahler DA, Demirel S, Hollander R, et al. High prevalence of suboptimal peak inspiratory flow in hospitalized patients with COPD: a real-world study. Chronic Obstr Pulm Dis. 2022;9(3):427–438. doi:10.15326/jcopdf.2022.0291
   PubMed Web of Science ®Google Scholar
• Singer D, Bengtson LGS, Elliott C, Buikema AR, Franchino-Elder J. Healthcare resource utilization, exacerbations, and readmissions among medicare patients with chronic obstructive pulmonary disease after long-acting muscarinic antagonist therapy initiation with soft mist versus dry powder inhalers. Int J Chron Obstruct Pulmon Dis. 2020;15:3239–3250. doi:10.2147/COPD.S284678
   PubMed Web of Science ®Google Scholar
• Cheng S-L. Comparison of effectiveness using different dual bronchodilator agents in chronic obstructive pulmonary disease treatment. J Clin Med. 2021;10(12):2649. doi:10.3390/jcm10122649
   PubMed Web of Science ®Google Scholar
• Ciciliani AM, Langguth P, Wachtel H. In vitro dose comparison of Respimat® inhaler with dry powder inhalers for COPD maintenance therapy. Int J Chron Obstruct Pulmon Dis. 2017;12:1565–1577. doi:10.2147/COPD.S115886
   PubMed Web of Science ®Google Scholar